Media headlines about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have trended somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiome Pharma earned a news impact score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.5679691519591 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Several research firms have recently issued reports on CRME. HC Wainwright set a $10.00 price objective on shares of Cardiome Pharma and gave the company a “buy” rating in a report on Wednesday. Mackie upgraded shares of Cardiome Pharma to a “buy” rating in a report on Friday, December 15th. Finally, Canaccord Genuity set a $5.00 price objective on shares of Cardiome Pharma and gave the company a “buy” rating in a report on Wednesday, March 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Cardiome Pharma currently has an average rating of “Hold” and an average target price of $5.67.
Cardiome Pharma stock opened at $2.32 on Friday. Cardiome Pharma has a 12-month low of $1.29 and a 12-month high of $4.84. The company has a market capitalization of $80.55, a PE ratio of -2.58 and a beta of 0.22. The company has a quick ratio of 4.71, a current ratio of 5.52 and a debt-to-equity ratio of 1.67.
ILLEGAL ACTIVITY WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cardiome-pharma-crme-share-price.html.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.